This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HANDELSMAN, D. J. Articles by TURTLE, J. R. Search for Related Content PubMed PubMed Citation Articles by HANDELSMAN, D. J. Articles by TURTLE, J. R.

Pharmacokinetics of Gonadotropin-Releasing Hormone: Comparison of Subcutaneous and Intravenous Routes^*

Department of Medicine, University of Sydney, and Departments of Endocrinology and Obstetrics and Gynecology, Royal Prince Alfred Hospital Camperdown, Sydney 2050, Australia

Address cell correspondence and requests for reprints to: Dr. D. J. Handelsman, Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, 1000 W. Carson Street, Torrance, California 90509.

Pulsatile administration of GnRH has been used to stimulate gonadal function in both hypogonadotropic men and women; however, deficient responses were observed with the sc in contrast to the iv route of hormone delivery. To clarify whether this was due to altered bioavailability, we compared the pharmacokinetics of these two routes of GnRH administration by bolus injection and steady state continuous infusion methods. Synthetic GnRH was administered by both sc and iv routes to 14 hypogonadotropic patients (11 women and 3 men) as a bolus (5 µg in 25, 100, or 250/A, sc, and 250 µl, iv; n = 6) or by continuous iv or sc infusion (3.17 µg/h for 6 h; n = 11). In single dose studies, plasma immunoreactive GnRH (IR-GnRH) peaks were earlier and higher (400 vs. 93.5 pg/ml) and returned to baseline sooner (<60 vs. >120 min) after iv than after sc bolus injection. Plasma IR-GnRH levels were lower between 1 and 5 min, but higher between 30–90 min after sc injection compared with iv bolus injection. During the continuous infusions, plateau levels of IR-GnRH between 2 and 6 h were 34% lower with sc delivery (67.5 vs. 102.4 pg/ml), indicating irreversible losses of about one third of GnRH injected sc. In patients undergoing pulsatile GnRH therapy delivered by programmed portable minipumps, plasma IR-GnRH profiles were highly damped after sc administration, but retained an intermittent pulse wave form with the iv route. These data suggest that pharmacokinetic differences in the sc and iv routes of GnRH administration are due to a combination of prolonged and delayed absorption with reduced bioavailability of GnRH via the sc route. The consequent damping of the plasma GnRH profiles with sc administration may contribute to differences in the clinical efficacy of pulsatile GnRH regimens, and specific modifications of pulsatile regimens may be required to adapt the physiological requirements of an intermittent plasma GnRH wave form to the damped and reduced bioavailability of sc GnRH therapy.

^* This work was supported by the National Health and Medical Research Council of Australia.

Received May 30, 1984.

This article has been cited by other articles:

				D. Madhukar and S. Rajender Hormonal Treatment of Male Infertility: Promises and Pitfalls J Androl, March 1, 2009; 30(2): 95 - 112. [Abstract] [Full Text] [PDF]

				M.-L. Kottler, S. Chauvin, N. Lahlou, C. E. Harris, C. J. Johnston, J.-P. Lagarde, P. Bouchard, N. R. Farid, and R. Counis A New Compound Heterozygous Mutation of the Gonadotropin-Releasing Hormone Receptor (L314X, Q106R) in a Woman with Complete Hypogonadotropic Hypogonadism: Chronic Estrogen Administration Amplifies the Gonadotropin Defect J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3002 - 3008. [Abstract] [Full Text]

				D. I. SPRATT, J. S. FINKELSTEIN, L. ST.L. O'DEA, T. M. BADGER, P. N. RAO, J. D. CAMPBELL, and W. F. CROWLEY Jr. Long-Term Administration of Gonadotropin-Releasing Hormone in Men with Idiopathic Hypogonadotropic Hypogonadism: A Model for Studies of the Hormone's Physiologic Effects Ann Intern Med, December 1, 1986; 105(6): 848 - 855. [Abstract] [PDF]